Enlivex completes dosing, follow-up for first patient in study of Allocetra

Enlivex Therapeutics (ENLV) announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra following injection into an affected joint in patients with psoriatic arthritis. No safety concerns were recorded following the dosing of the first patient. The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for psoriatic arthritis. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and secondary endpoints will include assessments of change from baseline in pain and other parameters of disease activity for up to 12 months